



Substitute for Form 1449/PTO		Application No.: 10/579,507	Filing Date: 5/15/06
Information Disclosure Statement by Applicant		First Named Inventor: Holm	
		Art Unit: 1633	Docket No.: 65,477-0033
U.S. PATENT DOCUMENTS Marvich			
Examiner Initials	Document No.	Date MM/DD/YYYY	Name
			Classification

FOREIGN PATENT DOCUMENTS				
Examiner Initials	Document No.	Date	Country	
/M.M./	WO 99/16873	08/04/1999	X	
/M.M./	EP 0 533 838	03/12/1997		
/M.M./	EP 0 931 830	07/03/2001		
/M.M./	WO 00/022136	20/04/2000		
/M.M./	WO 03/033692 A2	24/04/2003		
/M.M./	WO 03/033692 A3	24/04/2003		
/M.M./	WO 03/099859	04/12/2003		
/M.M./	WO 98/08856	05/03/1998		

NON-PATENT LITERATURE DOCUMENTS	
Examiner Initials	Author, title of the article, title of the item (book, magazine, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
/M.M./	Ahonen, et al.; <i>Antitumor Activity and Bystander Effect of Adenovirally Delivered Tissue Inhibitor of Metalloproteinases-3</i> 2002, <i>Mol Therapy</i> 5(6): 705-715
/M.M./	Amin, A., et al.; <i>9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901</i> 2004, <i>Urol. Oncol.</i> 22(5): 398-403
/M.M./	Arai, et al.; <i>Gene transfer of Fas ligand induces tumor regression vivo</i> 1997, <i>PNAS</i> 94(25): 13862-13867
/M.M./	Atadja, et al.; <i>Selective Growth Inhibition of Tumor Cells by a Novel Histone Deacetylase Inhibitor, NVP-LAQ824</i> 2004, <i>Cancer Res.</i> 64(2): 689-695
/M.M./	Avemmann, et al.; <i>Camptothecin, a specific inhibitor of type I DNA topoisomerase, induces DNA breakage at replication forks</i> 1988, <i>Mol. Cell. Biol.</i> 8(8): 3026-3034
/M.M./	Azzariti, A., et al.; <i>The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa™,</i>

/Maria Marvich/

10/01/2008

/M.M./	ZD1839) 2004, <i>Biochem Pharmacol.</i> 68(1): 135-144
	Balague, C., et al.; <i>Human Papillomavirus E6E7-Mediated Adenovirus Cell Killing: Selectivity of Mutant Adenovirus Replication in Organotypic Cultures of Human Keratinocytes</i> 2001, <i>J. Virol.</i> 75(16): 7602-7611
	Bargou, R.C., et al.; <i>Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression</i> , 1997, <i>Nat. Med.</i> 3(4): 447-450
	Barnett, B.G., et al.; <i>Targeted adenoviral vectors</i> 2002, <i>Biochimica Biophysica Acta</i> 1575: 1-14
	Binaschi, M., et al.; <i>Relationship between Lethal Effects and Topoisomerase II-Mediated Double-Stranded DNA Breaks Produced by Anthracyclines with Different Sequence Specificity</i> <i>Mol. Pharmacol.</i> 51(6): 1053-1059
	Bischof, M., et al.; <i>Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells</i> 2004, <i>Int. J. Radiat. Oncol. Biol. Phys.</i> 60(4): 1220-1232
	Boulanger & Blair; <i>Expression and interactions of human adenovirus oncoproteins</i> 1991, <i>Biochem. J.</i> 275: 281-299
	Braithwaite & Russell; <i>Induction of cell death by adenoviruses</i> 2001, <i>Apoptosis</i> 6(5): 359-370
	Brandt, K.; <i>Cancer Gene Therapy with Tissue Inhibitors of Metalloproteinases (TIMPs)</i> 2002, <i>Curr. Gene Therapy</i> 2(2): 255-271
	Braunstein, I., et al.; <i>Human Telomerase Reverse Transcriptase Promoter Regulation in Normal and Malignant Human Ovarian Epithelial Cells</i> 2001 <i>Cancer Res.</i> 61(14): 5529-5536
	Bridge & Ketner; <i>Interaction of adenoviral E4 and E1b products in late gene expression</i> 1990, <i>Virology</i> 174(2): 345-353
	Camphausen, K., et al.; <i>Enhancement of Xenograft Tumor Radiosensitivity by the Histone Deacetylase Inhibitor MS-275 and Correlation with Histone Hyperacetylation</i> 2004, <i>Clinical Cancer Res.</i> 10(18): 6066-6071
	Cantore, M., et al.; <i>Combined Irinotecan and Oxaliplatin in Patients with Advanced Pre-Treated Pancreatic Cancer</i> 2004, <i>Oncology</i> 67(2): 93-97
	Cao, G., et al.; <i>Comparison of carcinoembryonic antigen promoter regions isolated from human colorectal carcinoma and normal adjacent mucosa to induce strong tumor-selective gene expression</i> 1998, <i>Int. J. Cancer</i> 78(2): 242-247
	Chen, C-Y, et al.; <i>Nucleolin and YB-1 are required for JNK-mediated interleukin-2 mRNA stabilization during T-cell activation</i> 2000, <i>Genes & Development</i> 14(10): 1236-1248
	Chung, I., et al.; <i>Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells</i> 1999, <i>Cancer Gene Therapy</i> 6(2): 99-106
	Cin; <i>Genomic Changes in Endometrial Polyps Associated with Tamoxifen Show No Evidence for Its Action as an External Carcinogen</i> 1998, <i>Cancer Res.</i> 58(11): 2278-2281
	Coulson, J.M., et al.; <i>Tumour-specific arginine vasopressin promoter activation in small-cell lung cancer</i> 1999, <i>British J. Cancer</i> 80(12): 1935-1944
	Descamps, et al.; <i>Strategies for cancer gene therapy using adenoviral vectors</i> 1996, <i>J. Mol. Med.</i> 74(4): 183-189
▼	Dobbelstein, M., et al.; <i>Nuclear export of the E1B 55-kDa and E4 34-kDa adenoviral oncoproteins mediated by a rev-like signal sequence</i> 1997 <i>EMBO J.</i>
/M.M./	


/M.M./	16(14): 4276-4284
	Doronin, et al.; Tumor-Specific, Replication-Competent Adenovirus Vectors Overexpressing the Adenovirus Death Protein 2000, J. Virology 74(13): 6147-6155
	Dyson; The regulation of E2F by pRB-family proteins 1998, N. Genes & Development 12(15): 2245-2262
	Efthymiadis, A., et al.; The HIV-1 Tat Nuclear Localization Sequence Confers Novel Nuclear Import Properties 1998, JBC 273(3): 1623-1628
	Fribley, A., et al.; Proteasome Inhibitor PS-341 Induces Apoptosis through Induction of Endoplasmic Reticulum Stress-Reactive Oxygen Species in Head and Neck Squamous Cell Carcinoma Cells 2004, Mol. Cell Biol. 24(22): 9695-9704
	Friedberg, E.C.; Nuclear targeting sequences 1992, TIBS 17(9): 347
	Fueyo, J., et al.; A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo 2000, Oncogene 19(1): 2-12
	Gadi, et al.; A Long-Acting Suicide Gene Toxin, 6-Methylpurine, Inhibits Slow Growing Tumors after a Single Administration 2003, J. Pharmacol. And Exp. Therapeutics 304(3): 1280-1284
	Ganly, I., et al.; Replication and cytotoxicity of an E1B-attenuated adenovirus in drug-resistant ovarian tumor cells is associated with reduced apoptosis, 2001, Gene Therapy 8(5): 369-375
	Gilbert, et al.; Phase I Clinical and Pharmacokinetic Study of Irinotecan in Adults with Recurrent Malignant Glioma 2003, Clinical Cancer Res. 9(8): 2940-2949
	Goodrum & Ornelles; Roles for the E4 orf6, orf3, and E1B 55-Kilodalton Proteins in Cell Cycle-Independent Adenovirus Replication 1999, J. Virology 73(9): 7474-7488
	Gottesman & Pastan; Biochemistry of multidrug resistance mediated by the multidrug transporter 1993, Annu. Rev. Biochem 62: 385-427
	Hajitou, et al.; The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells 2002 FASEB J. 16(13): 1802-1804
	Hallenbeck, P.L., et al.; A Novel Tumor-Specific Replication-Restricted Adenoviral Vector for Gene Therapy of Hepatocellular Carcinoma 1999, Human Gene Therapy 10(10): 1721-1733
	Hasan, S., et al.; Transcription coactivator p300 binds PCNA and may have a role in DNA repair synthesis 2001, Nature 410: 387-391
	Heise, C., et al.; An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy 2001, Nature Medicine 6(10): 1134-1139
	Heise, et al.; ONYX-015, an E+B gene-attenuated adenovirus, causes tumor-specific cytotoxicity and antitumoral efficacy that can be augmented by standard chemotherapeutic agents, 1997, Nat. Med. 3(6): 639-645
	Helt & Galloway; Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins 2003, Carcinogenesis 24(2): 159-169
	Holm, P.S., et al.; YB-1 relocates to the nucleus in adenovirus infected cells and facilitates viral replication E2 gene expression through the E2-late promoter, 2002, J. Biol. Chem. 277(12): 10427-10434
↓	
/M.M./	Horwitz, M.S.; Adenovirus Immunoregulatory Genes and Their Cellular Targets 2001, Virology 279(1): 1-8

10/01/2008

/M.M./	Howe, J.A., et al.; <i>Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy</i> , 2000, Mol. Therapy 2(5): 485-493
	Hu, Z., et al.; <i>Transcriptional Activation of the MDR1 Gene by UV Irradiation. ROLE OF NF-κB AND Sp1</i> 2000, J. Biol. Chem. 275(4): 2979-2985
	Jaboin, et al.; <i>MS-27-275, an Inhibitor of Histone Deacetylase, Has Marked in Vitro and in Vivo Antitumor Activity against Pediatric Solid Tumors</i> 2002, Cancer Res. 62(21): 6108-6115
	Jans, D.A., et al.; <i>Nuclear targeting signal recognition: a key control point in nuclear transport?</i> 2000 Jun, Bioessays 22(6): 532-44
	Ji, et al.; <i>Induction of Apoptosis and Inhibition of Tumorigenicity and Tumor Growth by Adenovirus Vector-mediated Fragile Histidine Triad (FHIT) Gene Overexpression</i> 1999, Cancer Res. 59(14): 3333-3339
	Kamiya & Nakazatp; <i>The Expression of P73, P21 and MDM2 Proteins in Gliomas</i> 2002, J. Neurooncology 59(2): 143-149
	Keen, J.C., et al.; <i>A Novel Histone Deacetylase Inhibitor, Scriptaid, Enhances Expression of Functional Estrogen Receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2prime-deoxycytidine</i> 2003, Breast Cancer Res. Treat. 81(3): 177-186
	Kim, J.H., et al.; <i>Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor</i> 2004, Int. J. Radiat. Oncol. Biol. Phys. 59(4): 1174-1180
	Kindler, H.L., et al.; <i>9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium</i> 2004, Invest. New Drugs 22(3): 323-327
	Kitazono, et al.; <i>Enhanced Adenovirus Transgene Expression in Malignant Cells Treated with the Histone Deacetylase Inhibitor FR901228</i> 2001, Cancer Res. 61(17): 6328-6330
	Koike, K., et al.; <i>Nuclear translocation of the Y-box binding protein by ultraviolet irradiation</i> 1997, FEBS Lett. 417(3): 390-394
	Koyama, et al.; <i>Combined suicide gene therapy for human colon cancer cells using adenovirus-mediated transfer of Escherichia coli cytosine deaminase gene and Escherichia coli uracil phosphoribosyltransferase gene with 5-fluorocytosine</i> 2000, Cancer Gene Therapy 7(7): 1015-1022
	Lasham, A., et al.; <i>Regulation of the human fas promoter by YB-1, Pura and AP-1 transcription factors</i> 2000, Gene 252: 1-13
	Le, Q.T., et al.; <i>Phase I Study of Tirapazamine Plus Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy in Limited-Stage Small Cell Lung Cancer (S0004): A Southwest Oncology Group Study</i> 2004, Clinical Cancer Res. 10(16): 5418-5424
	Lockett, et al.; <i>Relative efficiency of tumor cell killing in vitro by two enzyme-prodrug systems delivered by identical adenovirus vectors</i> 1997, Clinical Cancer Res. 3(11): 2075-2080
	Lyons, R.H.; <i>Pentapeptide nuclear localization signal in adenovirus E1a</i> 1987, Mol. Cell Biol. 7(7): 2451-2456
▼	Magnusson, M.K., et al.; <i>Genetic Retargeting of Adenovirus: Novel Strategy Employing "Deknocking" of the Fiber</i> 2001, J. Virology 75(16): 7280-7289
/M.M./	Majumdar, A.S., et al.; <i>The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity</i>

/M.M./	encountered with constitutive promoters 2001, Gene Therapy 8(7): 568-578
	Majumdar, et al.; Efficacy of herpes simplex virus thymidine kinase in combination with cytokine gene therapy in an experimental metastatic breast cancer model 2000, Cancer Gene Therapy 7(7): 1086-1099
	Makino, Y., et al.; Structural and functional analysis of the human Y-box binding protein (YB-1) gene promoter 1996, Nucleic Acids Res. 24(10): 1873-1878
	McClue, S.J.; In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine) 2002, Int. J. Cancer 102(5): 463-468
	Mertens, P.R., et al.; Glomerular Mesangial Cell-specific Transactivation of Matrix Metalloproteinase 2 Transcription Is Mediated by YB-1 1997, JBC 272(36): 22905-22912
	Mizuguchi & Hayakawa; Adenovirus vectors containing chimeric type 5 and type 35 fiber proteins exhibit altered and expanded tropism and increase the size limit of foreign genes 2002, GENE 285: 69-77
	Nemunaitis, J.J., et al.; Phase I Study of Oral CI-994 in Combination with Gemcitabine in Treatment of Patients with Advanced Cancer 2003, Cancer J. 9: 58-66
	Nevins, J.R.; Mechanism of activation of early viral transcription by the adenovirus E1A gene product 1981, Cell 26(2): 213-220
	Nicklin, S.A., et al.; Ablating Adenovirus Type 5 Fiber-CAR Binding and HI Loop Insertion of the SIGYLP Peptide Generate an Endothelial Cell-Selective Adenovirus 2001, Mol. Therapy 4(6): 534-542
	Niculescu-Duvaz, et al.; Recent developments in gene directed enzyme prodrug therapy (GDEPT) for cancer 1999, Curr. Opin. Mol. Therapy 1(4): 480-486
	Nimmanapalli, R., et al.; Histone Deacetylase Inhibitor LAQ824 Both Lowers Expression and Promotes Proteasomal Degradation of Bcr-Abl and Induces Apoptosis of Imatinib Mesylate-sensitive or -refractory Chronic Myelogenous Leukemia-Blast Crisis Cells 2003, Cancer Res. 63(16): 5126-5135
	Oda, Y., et al.; Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma 1998, Clin. Cancer Res. 4(9): 2273-2277
	Ohga, T., et al.; Direct Involvement of the Y-box Binding Protein YB-1 in Genotoxic Stress-induced Activation of the Human Multidrug Resistance 1 Gene 1998, J. Biol. Chem. 273(11): 5997-6000
	Ohga, T., et al.; Role of the Human Y Box-binding Protein YB-1 in Cellular Sensitivity to the DNA-damaging Agents Cisplatin, Mitomycin C, and Ultraviolet Light 1996, Cancer Res. 56(18): 4224-4228
	Okamoto, T., et al.; Direct interaction of p53 with the Y-box binding protein, YB-1: a mechanism for regulation of human gene expression 2000, Oncogene 19(54): 6194-6202
	Opalka, et al.; Apoptotic Genes in Cancer Therapy 2002, Cell Tissues Organs 172(2): 126-132
	Ornelles & Shenk; Localization of the adenovirus early region 1B 55-kilodalton protein during lytic infection: association with nuclear viral inclusions requires the early region 4 34-kilodalton protein 1991, J. Virology 65(1): 424-429
	Piganeau, N., et al.; An Allosteric Ribozyme Regulated by Doxycycline 2000, Angew. Chem. Int. Ed. 39(23): 4369-4373
↓	Plumb, J.A., et al.; Pharmacodynamic Response and Inhibition of Growth of Human Tumor Xenografts by the Novel Histone Deacetylase Inhibitor PXD101 2003, Mol. Cancer Ther. 2(8): 721-728
/M.M./	

/M.M./	Rajendra, et al.; <i>Differential Effects of the Breast Cancer Resistance Protein on the Cellular Accumulation and Cytotoxicity of 9-Aminocamptothecin and 9-Nitrocamptothecin</i> 2003 <i>Cancer Res.</i> 63(12): 3228-3233
	Recchia, F., et al.; <i>Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX</i> 2004, <i>British J. Cancer</i> 91(8): 1442-1446
	Rodriguez, R., et al.; <i>Prostate Attenuated Replication Competent Adenovirus (ARCA) CN706: A Selective Cytotoxic for Prostate-specific Antigen-positive Prostate Cancer Cells</i> 1997, <i>Cancer Res.</i> 57(13): 2559-2563
	Rogers, et al.; <i>Killing Epstein-Barr virus-positive B lymphocytes by gene therapy: comparing the efficacy of cytosine deaminase and herpes simplex virus thymidine kinase</i> 1996, <i>Human Gene Therapy</i> 7: 2235-2245
	Sato, N., et al.; <i>FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells</i> 2004, <i>Int. J. Oncol.</i> 24(3): 679-685
	Shibao, K., et al.; <i>Enhanced coexpression of YB-1 and DNA topoisomerase II α genes in human colorectal carcinomas</i> 1999, <i>Int. J. Cancer</i> 83(6): 732-737
	Soff, et al.; <i>Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model</i> 1995, <i>J. Clin. Invest.</i> 96(6): 2593-2600
	Steegenga, W.T. et al.; <i>The large E1B protein together with the E4orf6 protein target p53 for active degradation in adenovirus infected cells</i> 1998, <i>Oncogene</i> 16(3): 349-357
	Stein, U., et al.; <i>Hyperthermia-induced Nuclear Translocation of Transcription Factor YB-1 Leads to Enhanced Expression of Multidrug Resistance-related ABC Transporters</i> 2001, <i>JBC</i> 276(30): 28562-69
	Stiewe, et al.; <i>Inactivation of Retinoblastoma (RB) Tumor Suppressor by Oncogenic Isoforms of the p53 Family Member p73</i> 2003, <i>J. Biol. Chem.</i> 278(16): 14230-14236
	Su, et al.; <i>Melanoma differentiation associated gene-7, mda-7/IL-24, selectively induces growth suppression, apoptosis and radiosensitization in malignant gliomas in a p53-independent manner</i> 2003, <i>Oncogene</i> 22(8): 1164-1180
	Sumantran, et al.; <i>Overexpression of Bcl-xS Sensitizes MCF-7 Cells to Chemotherapy-induced Apoptosis</i> 1995, <i>Cancer Res.</i> 55(12): 2507-2512
	Sundararajan, R. & White, E.; <i>E1B 19K Blocks Bax Oligomerization and Tumor Necrosis Factor Alpha-Mediated Apoptosis</i> 2001, <i>J. Virology</i> 75(16): 7506-7516
	Swamyathan, S.K., et al.; <i>Role of single-stranded DNA regions and Y-box proteins in transcriptional regulation of viral and cellular genes</i> 1998, <i>FASEB J.</i> 12(7): 515-522
	Tollefson, A., et al.; <i>Tumor-Specific, Replication-Competent Adenovirus Vectors Overexpressing the Adenovirus Death Protein</i> 1996, <i>J. Virology</i> 70(4): 2296-2306
	Toth, et al.; <i>Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein</i> 2003, <i>Cancer Gene Therapy</i> 10(3): 193-200
▼	Tralhao, et al.; <i>In vivo selective and distant killing of cancer cells using adenovirus-mediated decorin gene transfer</i> 2003, <i>FASEB J.</i> 17(3): 464-466
/M.M./	Tsukada, et al.; <i>An E2F-responsive Replication-selective Adenovirus Targeted to the Defective Cell Cycle in Cancer Cells: Potent Antitumoral Efficacy but No</i>

/M.M./	<i>Toxicity to Normal Cell</i> Cancer Res. 62(12): 3438-3447
	Vigushin, et al.; <i>Trichostatin A Is a Histone Deacetylase Inhibitor with Potent Antitumor Activity against Breast Cancer in Vivo</i> 2001, Clinical Cancer Res. 7(4): 971-976
	Weigel & Dobbstein; <i>The Nuclear Export Signal within the E4orf6 Protein of Adenovirus Type 5 Supports Virus Replication and Cytoplasmic Accumulation of Viral mRNA</i> 2000, J. Virology 74(2): 764-772
	Whittaker, G.R., et al.; <i>Nuclear Import and Export of Viruses and Virus Genomes</i> 1998, Virology 246(1): 1-23
	Wilhelm, S.M., et al.; <i>BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis</i> 2004, Cancer Res. 64(19): 7099-7109
	Wong, H.K., et al.; <i>Complementary functions of Ela conserved region 1 cooperate with conserved region 3 to activate adenovirus serotype 5 early promoters</i> , 1994, J. Virology 68(8): 4910-4920
	Wybranietz, W.A., et al.; <i>Enhanced suicide gene effect by adenoviral transduction of a VP22-cytosine deaminase (CD) fusion gene</i> 2001, Gene Therapy 8(21): 1654-1664
	Yamaguchi, et al.; <i>Enhancement of thymidine kinase-mediated killing of malignant glioma by BimS, a BH3-only cell death activator</i> 2003, Gene Therapy 10(5): 375-385
	Yoneda, Y.; <i>How Proteins Are Transported from Cytoplasm to the Nucleus</i> 1997, J. Biochem (Tokyo) 121(5): 811-817
	Zambetti, G.P., et al.; <i>A comparison of the biological activities of wild-type and mutant p53</i> 1993, FASEB J. 7(10): 855-865
	Zhang & Degroot; <i>Gene Therapy of a Rat Follicular Thyroid Carcinoma Model with Adenoviral Vectors Transducing Murine Interleukin-12</i> 2003, Endocrinology 144(4): 1393-1398
	Zhang, et al.; <i>Adenoviral-mediated Retinoblastoma 94 Produces Rapid Telomere Erosion, Chromosomal Crisis, and Caspase-dependent Apoptosis in Bladder Cancer and Immortalized Human Urothelial Cells but not in Normal Urothelial Cells</i> 2003, Cancer Res. 63(4): 760-765
	Zhang, et al.; <i>Identification of Human Uroplakin II Promoter and Its Use in the Construction of CG8840, a Urothelium-specific Adenovirus Variant That Eliminates Established Bladder Tumors in Combination with Docetaxel</i> 2002, Cancer Res. 62(13): 3743-3750
/M.M./	Zhang, et al.; <i>Monogene and Polygene Therapy for the Treatment of Experimental Prostate Cancers by Use of Apoptotic Genes bax and bad Driven by the Prostate-Specific Promoter ARR₂PB</i> 2002, Hum. Gene Ther. 13(17): 2051-2064

BH01836886.1
ID:DSN